Loading...
Refined Metals Corp.
RMC.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.12
CA$0.02(26.32%)

Over the past four quarters, Refined Metals Corp. demonstrated steady revenue growth, increasing from $0.00 in Q3 2022 to $0.00 in Q2 2023. Operating income reached -$99400.00 in Q2 2023, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$99400.00, reflecting operational efficiency. Net income rose to -$102149.00, with EPS at -$0.004. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan